Johnson & Johnson (BSP:JNJB34) Cyclically Adjusted Revenue per Share: R$13.26 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:JNJB34 Johnson & Johnson BSP:JNJB34
80 GF Score
Price R$87.16
GF Value R$65.12
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson Cyclically Adjusted Revenue per Share?

Johnson & Johnson BSP:JNJB34 -0.83% 80 Cyclically Adjusted Revenue per Share is R$13.26 as of Jun. 2026. GuruFocus rates BSP:JNJB34 with a GF Score™ of 80/100 and a GF Value™ of R$65.12 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Johnson & Johnson's adjusted revenue per share for the three months ended in Jun. 2026 was R$3.543. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$13.26 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Johnson & Johnson's average Cyclically Adjusted Revenue Growth Rate was 5.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Johnson & Johnson was 10.10% per year. The lowest was 3.30% per year. And the median was 7.10% per year.

As of today (2026-08-07), Johnson & Johnson's current stock price is R$87.16. Johnson & Johnson's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was R$13.26. Johnson & Johnson's Cyclically Adjusted PS Ratio of today is 6.57.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Johnson & Johnson was 6.85. The lowest was 3.98. And the median was 5.05.


Johnson & Johnson  (BSP:JNJB34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Johnson & Johnson's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=87.16/13.26
=6.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Johnson & Johnson was 6.85. The lowest was 3.98. And the median was 5.05.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Johnson & Johnson Cyclically Adjusted Revenue per Share Related Terms


Johnson & Johnson Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Johnson & Johnson's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson Cyclically Adjusted Revenue per Share Chart

Johnson & Johnson Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.64 11.70 11.07 14.62 13.56

Johnson & Johnson Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.23 13.13 13.56 13.05 13.26

BSP:JNJB34 vs ABBV, MRK, LLY: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Johnson & Johnson Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Cyclically Adjusted PS Ratio falls into.


BSP:JNJB34
80GF Score
Johnson & Johnson BSP:JNJB34
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Johnson & Johnson Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Johnson & Johnson's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.543/333.9520*333.9520
=3.543

Current CPI (Jun. 2026) = 333.9520.

Johnson & Johnson Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.388 241.428 1.920
201612 1.464 241.432 2.025
201703 1.345 243.801 1.842
201706 1.510 244.955 2.059
201709 1.499 246.819 2.028
201712 1.618 246.524 2.192
201803 1.601 249.554 2.142
201806 1.924 251.989 2.550
201809 2.043 252.439 2.703
201812 1.937 251.233 2.575
201903 1.899 254.202 2.495
201906 1.964 256.143 2.561
201909 2.132 256.759 2.773
201912 2.124 256.974 2.760
202003 2.523 258.115 3.264
202006 2.379 257.797 3.082
202009 2.843 260.280 3.648
202012 2.887 260.474 3.701
202103 3.137 264.877 3.955
202106 2.925 271.696 3.595
202109 3.071 274.310 3.739
202112 1.378 278.802 1.651
202203 2.915 287.504 3.386
202206 3.030 296.311 3.415
202209 2.627 296.808 2.956
202212 2.628 296.797 2.957
202303 2.785 301.836 3.081
202306 2.652 305.109 2.903
202309 2.757 307.789 2.991
202312 2.874 306.746 3.129
202403 2.921 312.332 3.123
202406 3.328 314.175 3.537
202409 3.417 315.301 3.619
202412 3.771 315.605 3.990
202503 3.467 319.799 3.620
202506 3.629 322.561 3.757
202509 3.532 324.800 3.632
202512 3.657 324.054 3.769
202603 3.431 330.213 3.470
202606 3.543 333.952 3.543

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of R$13.26 mean?
Johnson & Johnson (BSP:JNJB34) has a Cyclically Adjusted Revenue per Share of R$13.26 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Johnson & Johnson and its competitors.
Is Johnson & Johnson's Cyclically Adjusted Revenue per Share too high?
Johnson & Johnson's current Cyclically Adjusted Revenue per Share is R$13.26. Overall, Johnson & Johnson has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's Cyclically Adjusted Revenue per Share compare to ABBV and MRK?
Johnson & Johnson's Cyclically Adjusted Revenue per Share of R$13.26 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Johnson & Johnson and its competitors. Johnson & Johnson's current Cyclically Adjusted Revenue per Share is R$13.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (BSP:JNJB34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$65.12, compared to a current price of R$87.16 — trading 33.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is R$13.26. Johnson & Johnson's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Johnson & Johnson (BSP:JNJB34), the current Cyclically Adjusted Revenue per Share is R$13.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Johnson & Johnson (BSP:JNJB34) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of R$87.16 is trading 33.8% above its estimated GF Value™ of R$65.12. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for BSP:JNJB34:

  • Cyclically Adjusted Revenue per Share: R$13.26
  • GF Value™: R$65.12 vs. price of R$87.16 (33.8% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the BSP:JNJB34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
80GF Score

Get the complete analysis for BSP:JNJB34

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$87.16
Price
R$65.12
GF Value